Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;7(3):922-930.
doi: 10.1002/cam4.1370. Epub 2018 Feb 23.

Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study

Weikai Xiao  1 , Shaoquan Zheng  1 , Peng Liu  1 , Yutian Zou  1 , Xinhua Xie  1 , Ping Yu  1 , Hailin Tang  1 , Xiaoming Xie  1
Affiliations

Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study

Weikai Xiao et al. Cancer Med. 2018 Mar.

Abstract

The risk factors for morbidity and mortality in breast cancer lung metastases (BCLM) patients still remain poorly identified. The aim of this study was to assess the incidence and survival of BCLM and associated risk factors. Patients with BCLM were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariate logistic regression analysis was used to determine the risk factors for BCLM. Predictors of factors associated with death were analyzed in Cox regression and Fine and Gray's test. Of the 11568 patients with stage IV breast cancer, 4213 (36.4%) had BCLM and 1214 (10.5%) had metastases confined to lungs. The median survival time for patients with BCLM was 21 months, and 15.5% of the patients were alive more than 3 years. The tumor subtype distribution was 45.3% HR- /HER2- , 12.2% HR+ /HER2+ , 7.8% HR- /HER2+, and 15.0% triple-negative subtype. Compared with patients without BCLM, those with BCLM were more likely to be aged, female, black, higher tumor grade, HR- /HER2+ , HR+ /HER2+, and triple-negative subtypes at diagnosis. Survival analysis showed that the aged, black race, HR- /HER2+ , triple-negative subtype, higher grade were the independent risk factor for BCLM patients' survival, while HR+ /HER2+ subtype, insured status, and married status suggested better prognosis. In conclusion, the incidence and prognosis of BCLM varied by tumor subtypes, age, and race. Elderly patients with HER2-positive or triple-negative tumors were more likely to have BCLM.

Keywords: Breast cancer; incidence; lung metastases; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival and subtype‐stratified survival among patients with lung metastases from breast cancer. The overall survival (A), survival stratified by subtype (B), and survival stratified by the extent of extrapulmonary metastatic disease (C). HER2, human epidermal growth factor receptor 2; HR, hormone receptor. + Denotes positive; − denotes negative.
See this image and copyright information in PMC

References

    1. Kennecke, H. , Yerushalmi R., Woods R., Cheang M. C., Voduc D., Speers C. H., et al. 2010. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28:3271–3277. - PubMed
    1. Smid, M. , Wang Y., Zhang Y., Sieuwerts A. M., Yu J., Klijn J. G., et al. 2008. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68:3108–3114. - PubMed
    1. Lee, Y. T. 1983. Breast carcinoma: pattern of metastasis at autopsy. J. Surg. Oncol. 23:175–180. - PubMed
    1. Diaz‐Canton, E. A. , Valero V., Rahman Z., Rodriguez‐Monge E., Frye D., Smith T., et al. 1998. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann. Oncol. 9:413–418. - PubMed
    1. Yhim, H. Y. , Han S. W., Oh D. Y., Han W., Im S. A., Kim T. Y., et al. 2010. Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy. Cancer‐Am. Cancer Soc. 116:2890–2901. - PubMed

Publication types